Abstract Number: 0046 • ACR Convergence 2026
Metabolic-epigenetic regulation of interferon-responsive CD38 in systemic lupus erythematosus
Background/Purpose: CD38 expression is increased in T cells from patients with systemic lupus erythematosus (SLE), yet the mechanisms sustaining persistent CD38 dysregulation remain unclear. We…Abstract Number: 1008 • ACR Convergence 2026
Nonresponse to hydroxychloroquine in cutaneous lupus is associated with increased type I interferon signatures in epidermal and stromal cells.
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease driven by type I interferon (IFN) signaling across stromal and immune cell populations. Hydroxychloroquine…Abstract Number: 1573 • ACR Convergence 2026
Automated Synovial Mast Cell Quantification Reveals Associations with Pain, Obesity and Interferon Related Inflammation in Osteoarthritis
Background/Purpose: Mast cells have been implicated in the pathogenesis of osteoarthritis (OA) [1]. We hypothesized that mast cell infiltration in synovial tissue may contribute to…Abstract Number: 2006 • ACR Convergence 2026
Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, and Sjogren’s Disease, All Characterized by Autoantibodies Targeting RNA-binding Proteins, Comprise a Group of Systemic Interferonopathies
Background/Purpose: In most patients with systemic lupus erythematosus (SLE), type I interferon (IFN-I) production is sustained, contributing to protean immune system alterations, autoimmunity and tissue…Abstract Number: 2854 • ACR Convergence 2026
LUB006, A Novel and Potent anti-IFNAR1-TACI Antibody Fusion Protein, Demonstrates Synergistic Efficacy in an Systemic Lupus Erythematosus Model by Dual Pathway Inhibition
Background/Purpose: The roles of IFN-1 and BAFF/APRIL in Systemic Lupus Erythematosu (SLE) pathogenesis have been well established, and therapies targeting IFNAR1 and BAFF/APRIL have been…Abstract Number: 0051 • ACR Convergence 2026
Single-cell Transcriptomic Profiling Reveals Distinct Neutrophil States and Functional Features in Systemic Lupus Erythematosus
Background/Purpose: Neutrophils are increasingly recognized as heterogeneous immune cells in systemic lupus erythematosus (SLE), yet their disease-associated transcriptional states, functional properties, and RNA-regulatory features remain…Abstract Number: 1020 • ACR Convergence 2026
Interferon Pathway-High Plasmacytoid Dendritic Cells Define Immune-Stromal Niches in Cutaneous Lupus
Background/Purpose: Cutaneous lupus erythematosus (CLE) is characterized by elevated interferon (IFN) signatures and inflammatory skin lesions. Plasmacytoid dendritic cells (pDCs) are implicated in CLE pathogenesis…Abstract Number: 1595 • ACR Convergence 2026
Lupus Myositis, a Type 1 Interferon Driven Necrotizing Myopathy with Regional Heterogeneity
Background/Purpose: Lupus myositis (LM) is an underrecognized entity, whose pathological features significantly overlap with idiopathic inflammatory myopathies (IIMs). Currently, no standardized histopathological criteria or immunohistochemical…Abstract Number: 2012 • ACR Convergence 2026
Interferon Response Genes and Joint Damage in Psoriatic Arthritis: A Sex-Stratified Analysis
Background/Purpose: Sex differences in the expression of Psoriatic Arthritis (PsA) have been noted, with females having more peripheral inflammatory arthritis, but less radiographic joint damage…Abstract Number: 2856 • ACR Convergence 2026
First-in-class Oral IRF5 Degrader, KT-579, Demonstrates Significant Activity Alone or in the Presence of Background Therapies in Preclinical Lupus Models
Background/Purpose: SLE is a chronic and heterogenous autoimmune disease with multi-organ manifestations. Background therapy maintenance includes hydroxychloroquine (HCQ) while aiming to minimize chronic glucocorticoid or…Abstract Number: 0055 • ACR Convergence 2026
Twenty Year Longitudinal Assessment of 13 Type I Interferon Antibodies in 675 Lupus Patients: Correlations with disease activity, suppression of interferon responsive genes, patterns of reactivity over time and specificity of antibody binding
Background/Purpose: Antibodies to cytokines are increased in lupus. Their impact on health and disease are not understood. Prior reports of anti-Type I IFN Abs found…Abstract Number: 1025 • ACR Convergence 2026
Unraveling the contribution of IFIH1 in systemic lupus erythematosus pathogenesis
Background/Purpose: An altered type I interferon (IFN I) program has been strongly connected with systemic lupus erythematosus (SLE) and a severe complication of the disease,…Abstract Number: 1597 • ACR Convergence 2026
Monitoring Disease Activity in Dermatomyositis using Blood Microsampling: A Pilot Study
Background/Purpose: In dermatomyositis (DM), disease flares are unpredictable and often detected weeks to months after their onset. Interferon-related gene signatures are implicated in DM, but…Abstract Number: 2042 • ACR Convergence 2026
A Homozygous IRAK2 Q127H Variant Drives Exaggerated Innate and Interferon Signaling in IFN-high Still’s Disease
Background/Purpose: Still's disease (systemic juvenile idiopathic arthritis (sJIA) in children and adult-onset Still's disease (AOSD) in adults) is generally considered a non-monogenic autoinflammatory disorder marked…Abstract Number: 2868 • ACR Convergence 2026
Distinct Plasma Cytokine Profiles Across Rheumatic Diseases Reveal an RA-Specific Interstitial Lung Disease Signature
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) cause significant morbidity and mortality through diverse mechanisms. Major implicated drivers include interferon (IFN), T cell, inflammasome/IL-6, and TNF-α…
ACR Meeting Abstracts